Neurocrine Beats Teva To Tardive Dyskinesia Market With Ingrezza
Executive Summary
Neurocrine secured FDA approval for the first drug to treat tardive dyskinesia, a large market that crosses multiple diseases and has blockbuster potential.
You may also be interested in...
Neurocrine Will Delay Ongentys Launch, But It Thinks Differentiation Is Clear
Ongentys, now approved as adjunctive therapy in Parkinson’s disease, will offer a convenience advantage over generic COMT inhibitors. The company will delay launch due to pandemic and manufacturing issues.
Teva Set For Immediate US Launch Of Austedo In Tardive Dyskinesia
FDA-approved labeling includes boxed warning for depression and suicidality, though this is specific for Huntington's disease patients, who are prone to these conditions.
Neurocrine Blames Sub-Par Dosing For Ingrezza Study Failure
Neurocrine's stock fell 9% on May 24 after the company said a closely-watched Phase II study for Ingrezza in pediatric Tourette's syndrome failed, but blamed a sub-therapeutic dose for the disappointing results. Most analysts gave the prospects for a higher dose study the benefit of the doubt.